Tyra Biosciences Q2 net loss $18.7M; cash remains $373.8M; IND cleared for TYRA-430; ACH IND on track

Tyra Biosciences, Inc.

2024-Q2 EPS reported -$0.67

Q2 net loss $18.7M ($13.3M in Q2 2023); R&D $18.0M; cash $373.8M, runway through at least 2026.
FDA cleared IND for TYRA-430 (FGFR4/3 biased inhibitor) for Phase 1 in HCC and other solid tumors.
TYRA-300: preclinical proof-of-concept in hypochondroplasia; ACH IND submission on track for 2H24.
CMO Hiroomi Tada to depart by year-end; external search underway; S&T Committee guiding transition.
SURF301 Phase1 initial results for TYRA-300 expected at a scientific congress in 2H24.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.